The Academy鈥檚 March 16 conversation about the nation鈥檚 rapidly changing vaccine policy and the implications for pediatricians, public health, and production was literally interrupted with breaking vaccine news. Mid-conversation, a court ruling was issued that blocked the administration鈥檚 attempts to significantly change vaccine policy; the development underscored the volatility of the situation and the value of analyzing it with perspectives from clinical care, regulation, and industry.
The conversation was moderated by Laurie Patton and featured Paul Offit [Chief, Division of Infectious Diseases; Director, Vaccine Education Center, Children's Hospital of Philadelphia], Norman Baylor [Former Director, FDA鈥檚 Office of Vaccines Research and Review], and Penny Heaton [Global Head, Office of the Chief Medical Officer, Johnson & Johnson]. Together, they explored how recent policy shifts are unsettling not only vaccine governance, but also public trust in the institutions behind it.
Offit opened with a sharp critique of recent federal actions affecting childhood vaccine recommendations, arguing that changes to the Centers for Disease Control and Prevention (CDC) schedule were made without scientific justification, creating the false impression that the evidence had changed when it had not. While he acknowledged that many pediatricians and professional societies are continuing to rely on established science-based schedules rather than the altered federal guidance, he cautioned that the impacts of this are still widely felt.
Baylor broadened that concern by focusing on the Food and Drug Administration (FDA). He argued that vaccine regulation depends on transparency: clear standards, public advisory committee meetings, and a predictable process for evaluating risk and benefit. Recent reversals, therefore, weaken that transparency and create confusion for both industry and the public. Baylor stressed that the problem goes far beyond the decisions being made to impact public trust in process and expertise.
Heaton then added a private sector perspective, showing how changes in policy and public confidence are already affecting the vaccine industry. Uncertainty shakes investor confidence, making manufacturers less willing to commit to production, and threatening the development of vaccines that may be needed years from now. Because vaccine production relies on long timelines and stable demand, disruptions in policy today can damage research, supply chains, and innovation well into the future.
The timeliness of the event was underscored by breaking news that a federal judge had blocked recent changes to vaccine policy by the Department of Health and Human Services (HHS) and allowed the upcoming meeting of the Advisory Committee on Immunization Practices (ACIP), the expert panel that advises the Centers for Disease Control and Prevention on vaccine recommendations, to proceed. Patton brought the update into the discussion, prompting the panelists to reflect in real time on what such reversals might mean. Even as the ruling offered a measure of short-term relief, it reinforced the volatility that makes it harder for agencies, clinicians, companies, and the public to know who to trust and how to plan.
Throughout the discussion, Patton asked the panel to address the larger problem of vaccine hesitancy and consider the roots of mistrust. The speakers agreed that restoring confidence will require more than repeating established facts, but stronger transparency and a more accurate account of the limits of vaccines. The panelists acknowledged that vaccine skeptics are sometimes responding to real communication failures or process breakdowns, even when their broader conclusions are wrong.
The panel ended with a set of practical calls to action. Heaton urged scientists to keep publishing peer-reviewed work, communicating publicly, and engaging with journalists so that misinformation does not rush in to fill the gaps. She also pointed to a wider set of responsibilities: artists and communicators can help tell more compelling public stories about vaccines, philanthropists can make strategic investments where the ecosystem is most vulnerable, and attendees can support the professional societies working to uphold evidence-based vaccine policy.
While the panelists warned that recent damage may be lasting, they also argued that science, transparency, and sustained public engagement remain the strongest tools for protecting one of public health鈥檚 most consequential achievements.
This event was an Academy pop-up discussion.
Learn more and register for future events here.